Cancer: PLK4 inhibitor shows potent antitumour activity

Download Cancer: PLK4 inhibitor shows potent antitumour activity

Post on 12-Feb-2017

213 views

Category:

Documents

1 download

Embed Size (px)

TRANSCRIPT

  • A N T I V I R A L S

    Engineered Tcells as broad-spectrum antiviralsImmunocompromised individuals often have a number of active viral infections. Here, the development of an adoptive transfer strategy is presented, using multivirus-specific Tcells (mVSTs) generated by direct stimulation of peripheral blood mononuclear cells with overlapping peptide libraries that incorporate antigens from five common viruses. The mVSTs were tested in a small clinical trial in recipients of allogenic transplants with up to four active infections, where they showed sustained and broad antiviral activity. Importantly, mVSTs can be rapidly produced and tailored to desired specifications.ORIGINAL RESEARCH PAPER Papadopoulou, A. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl. Med. 6, 242ra83 (2014)

    C A N C E R

    Epigenetic target in Hedgehog-driven tumoursThe Hedgehog (Hh) pathway can drive oncogenesis, and current strategies to target it mainly focus on inhibitors of the Gprotein-coupled receptor Smoothened (SMO). SMO activates the downstream transcription factors GLI1 and GLI2, which transactivate Hh target genes. SMO inhibitors have demonstrated clinical efficacy, but resistance usually develops. Tang et al. now report that the epigenetic regulator BRD4, a BET bromodomain protein, controls GLI transcription by binding to the GLI1 and GLI2 promoters. The BRD4 inhibitor JQ1 was shown to downregulate Hh signalling, and had antitumour activity even in tumours that were resistant to SMO inhibitors.ORIGINAL RESEARCH PAPER Tang, Y. et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Med. 20, 732740 (2014)

    M A L A R I A

    Complete protection with AMA1RON2 complex?The apical membrane antigen 1 (AMA1), a crucial protein for the invasion of Plasmodium merozoites into red blood cells, is a leading malaria vaccine candidate, but has shown little efficacy in clinical trials so far. Here, the authors show that vaccination with a complex of AMA1 and rhoptry neck protein 2 (RON2) can induce antibody-mediated complete protection against a lethal Plasmodium yoelii challenge in mice. It is likely that the protein complex mimics the functional form of the proteins more closely, thereby inducing more potent protective antibodies. ORIGINAL RESEARCH PAPER Srinivasan, P. et al. Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc. Natl Acad. Sci. USA 111, 1031110316 (2014)

    C A N C E R

    PLK4 inhibitor shows potent antitumour activityPolo-like kinase 4 (PLK4) was identified as an anticancer target in an RNA interference (RNAi) screen in human breast cancers and cell lines, and the small molecule CFI-400945 was found to be a potent, selective and orally available PLK4 inhibitor. In vitro studies showed that CFI-400945 treatment recapitulates the hallmarks of genetic PLK4 inhibition, and in vivo studies showed it was well tolerated and had potent antitumour activity in breast cancer xenograft models, particularly those deficient in the tumour suppressor PTEN a synthetic lethal interaction partner of PLK4. CFI-400945 has entered Phase I clinical trials.ORIGINAL RESEARCH PAPER Mason, J. M. et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell 26, 163176 (2014)

    IN BRIEF

    R E S E A R C H H I G H L I G H T S

    NATURE REVIEWS | DRUG DISCOVERY VOLUME 13 | SEPTEMBER 2014

    2014 Macmillan Publishers Limited. All rights reserved

Recommended

View more >